Conmed Corp

Conmed Corp(CNMD)股票分析

$49.250

-0.187 (-0.38%)收盘时

Loading chart…
最高
49.720
开盘
49.030
成交量加权均价
49.09
成交量
343.12K
市值
2.08B
最低
48.310
成交额
16.84M
企业价值/息税折旧摊销前利润(TTM)
8.07

CONMED Corporation is a medical technology company which provides devices and equipment for surgical procedures. Its products are used by surgeons and other healthcare professionals in a variety of specialties, including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. Its product line consists of orthopedic surgery and general surgery. Orthopedic surgery consists of sports medicine instrumentation and lower extremities instrumentation and implants, small bone, large bone and specialty-powered surgical instruments as well as imaging systems for use in minimally invasive surgical procedures and service fees related to the promotion and marketing of sports medicine allograft tissue. General surgery consists of a complete line of endo-mechanical instrumentation for minimally invasive laparoscopic and gastrointestinal procedures, smoke evacuation devices, a line of cardiac monitoring products as well as electrosurgical generators and related instruments.

AI 分析 of Conmed Corp (CNMD)

买入

Conmed Corp (CNMD) is a good buy right now, trading at $46.72, which is below the average analyst target price of $111.62. The stock has shown a strong 5-day change of +5.18% and a year-to-date change of +15.30%, indicating positive momentum. However, the main risk is its forward P/E ratio of 27.17, which suggests that the stock may be overvalued if growth does not meet expectations.

分析师评级(6)

上行空间 +1.52%
持有
2 买入
4 持有
0 卖出
当前: 49.25
最低
41.00
平均
50.00
最高
55.00

JPMorgan

2026-07-30

目标价

$45

中性

Piper Sandler

2026-07-30

目标价

$45

中性

BMO Capital

2026-07-08

目标价

$36

Market Perform

BofA

2026-06-29

目标价

$40

跑输大盘

BofA

2026-05-18

目标价

$40

中性

估值指标

Conmed Corp(CNMD)当前预期市盈率为 27.17,5 年平均预期市盈率为 24.47。

预期市盈率

合理
5 年均值 P/E
24.47
当前P/E
27.17
高估
34.11
低估
14.82

预期 EV/EBITDA

低估
5 年均值 EV/EBITDA
13.75
当前EV/EBITDA
8.07
高估
18.26
低估
9.24

预期市销率

低估
5 年均值 P/S
1.97
当前P/S
1.03
高估
2.88
低估
1.05

Alphio AI 对 CNMD 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%CNMD

$71.75

情景价格

基

基准

基准 · 50%CNMD

$68.33

情景价格

悲

悲观

悲观 · 25%CNMD

$67.79

情景价格

持有 CNMD 的大户

P

Paradigm Capital Management, Inc.

+ 持有CNMD

-20.90%

3个月收益率

事件时间线

2026-09-21 (ET)

06:30:00

Avantor Appoints Todd Garner as EVP and CFO

2026-07-29 (ET)

16:31:00

Raises FY26 Revenue View to $1.358B-$1.373B

16:31:00

CONMED Reports Q2 Revenue of $343.5M, Exceeds Expectations

2026-07-22 (ET)

07:30:00

CONMED Expands AirSeal Robotic Solution Indication

2026-07-13 (ET)

12:30:00

Major Averages Decline Amid Rising Geopolitical Tensions

资讯

CNMD 常见问题 —— 由 Alphio AI 解答

CONMED Corporation is a medical technology company which provides devices and equipment for surgical procedures. Its products are used by surgeons and other healthcare professionals in a variety of specialties, including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. Its product line consists of orthopedic surgery and general surgery. Orthopedic surgery consists of sports medicine instrumentation and lower extremities instrumentation and implants, small bone, large bone and specialty-powered surgical instruments as well as imaging systems for use in minimally invasive surgical procedures and service fees related to the promotion and marketing of sports medicine allograft tissue. General surgery consists of a complete line of endo-mechanical instrumentation for minimally invasive laparoscopic and gastrointestinal procedures, smoke evacuation devices, a line of cardiac monitoring products as well as electrosurgical generators and related instruments. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).

Conmed Corp (CNMD) is a good buy right now, trading at $46.72, which is below the average analyst target price of $111.62. The stock has shown a strong 5-day change of +5.18% and a year-to-date change of +15.30%, indicating positive momentum. However, the main risk is its forward P/E ratio of 27.17, which suggests that the stock may be overvalued if growth does not meet expectations.

6 analysts cover CNMD: 2 rate it Buy, 4 Hold and 0 Sell. The average price target is 50.00.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易